Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
51.68 USD | +0.98% | -1.28% | -17.69% |
24.04. | INCYTE CORPORATION : Oppenheimer bekräftigt seine Kaufempfehlung | ZM |
23.04. | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
ETFs investiert in Incyte Corporation
Name | Gewichtung | Volumen | % 1. Jan. | Investm. Rating |
---|---|---|---|---|
14,55% | 215 M€ | +10.68% | - | |
2,94% | 1 M€ | -5.79% | - | |
2,88% | 1 M€ | 0.00% | - | |
2,10% | 4 M€ | +20.15% | ||
1,95% | 16 M€ | -3.37% | ||
1,68% | 0 M€ | 0.00% | - | |
1,65% | 2 M€ | +6.77% | ||
1,54% | 8 M€ | +2.44% | ||
1,50% | 0 M€ | 0.00% | - | |
0,41% | 13 M€ | -.--% | - | |
0,41% | 4 M€ | -.--% | - | |
0,41% | 3 M€ | +15.16% | - | |
0,37% | 18 M€ | +3.79% | - | |
0,29% | 105 M€ | +6.17% | ||
0,20% | 8 M€ | +3.41% | - | |
0,20% | 33 M€ | +0.25% | - | |
0,20% | 18 M€ | +3.41% | - | |
0,17% | 9 M€ | -.--% | - | |
0,17% | 393 M€ | +5.25% | ||
0,14% | 5 M€ | -72.95% | - | |
0,08% | 9 M€ | +6.26% | - | |
0,08% | 7 M€ | +0.11% | - | |
0,07% | 219 M€ | +17.17% | - | |
0,07% | 1 448 M€ | -.--% | - |
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-17.69% | 11.6 Mrd. | |
-4.66% | 86.13 Mrd. | |
+1.32% | 39.82 Mrd. | |
-19.27% | 30.42 Mrd. | |
+57.86% | 25.23 Mrd. | |
-43.00% | 11.51 Mrd. | |
-9.14% | 11.95 Mrd. | |
+5.24% | 8.71 Mrd. | |
-8.42% | 8.12 Mrd. | |
+2.29% | 7.72 Mrd. |
- Börse
- Aktien
- 896133 Aktie
- ETFs Incyte Corporation